Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment

This thought-provoking book covers the full range of psychopharmacologic practice in textbook fashion, offering a fresh and comprehensive self-examination. Unlike conventional texts of psychopharmacology, this text speaks directly to clinicians who have started to question the limitations of psychopharmacologic claims and the rigid confines of DSM-5 diagnoses. Drawing from their clinical and research experience as well as new literature, the well-published authors provide a new perspective that encourages readers to reevaluate established practices and embrace that medication is just one component of treatment and has limits. The book could be used by psychiatric residents in their course of study, by clinical psychology students taking a psychopharmacology course, or by psychiatrists curious to get a readable but comprehensive look at new critical viewpoints in psychopharmacology that have changed since they were taught. Many neuroscience students who are looking for areview of clinical effects to guide their basic research may also find the proposed text more useful than those texts that collate clinical trials.

Current texts are for specialized scientists or are part of multi-authored texts which list drugs alphabetically with no conceptual framework, or books that pretend that each biochemical drug property has a clear and known clinical result presented in cartoon style. Some lesser known texts for psychology or nursing students are not authoritative. Others aimed at patients or families are too simplistic for clinicians. The authors' goal was to create a unified text expressing their view of psychopharmacology, its evidence base, the unity of its essential principles, and its independence of DSM or ICD diagnosis.

Several new history books describe the "rise and fall" of psychopharmacology, the corruption of big pharma and the failure of large controlled clinical trials. Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment ensures that young clinicians are aware of and understand this critical zeitgeist but aware also of the essential core of psychopharmacology and the evidence upon which it rests.

Robert Haim Belmaker, Division of Psychiatry, Ben-Gurion University of the Negev, Israel. belmaker@bgu.ac.il

Prof. Robert Haim Belmaker is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel and is now Emeritus. He was President of the International College of Neuropsychopharmacology 2008-2010, Vice President of the International Society for Bipolar Disorders 2012-2014, President of the Israel Psychiatry Association 2015-2018 and is Fellow Emeritus of the American College of Neuropsychopharmacology. He has co-edited 18 books in psychopharmacology and authored over 400 original papers.

Pesach Lichtenberg, M.D., The Hebrew University in Jerusalem; Soteria Israel; and the Jerusalem Mental Health Center.

pesach.lichtenberg@mail.huji.ac.il

Prof. Pesach Lichtenberg has directed acute care psychiatric wards for 25 years, currently in the Jerusalem Mental Health Center. He served as the Academic Chair of Psychiatry at the Faculty of Medicine of the Hebrew University in Jerusalem. His academic work has covered psychopharmacology, diagnosis, hypnosis and placebo. His clinical and research activity in recent years focuses on the Soteria model for psychosis, which he brought to Israel, and which has catalyzed far-reaching changes in the public mental health care system.